GHRS

GH Research Plc · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website ghres.com
Employees(FY) 32
ISIN IE000GID8VI0

Performance

-11.38%

-28.72%

-12.18%

-42.73%

+18.1%

YTD

+28.76%

Profile

GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies to treat psychiatric and neurological disorders. The company develops 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable mebufotenin product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an intravenous mebufotenin product candidate; and GH003, an intranasal mebufotenin product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.

Advanced Technical Analysis

Technical Analysis of GHRS 2024-12-20

The stock indicators reflect a predominantly bearish sentiment, with the Moving Average Score at 3 and the Technical Score at 21, both indicating weak performance. The Oscillators Score of 40 suggests a neutral stance, but overall, the combined scores point to a lack of bullish momentum in the market.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of GHRS

Stock Rank

Recent News & Updates

2024-11-20 09:55
Does GH Research (GHRS) Have the Potential to Rally 225.18% as Wall Street Analysts Expect?(Zacks)
2024-11-17 18:19
Weekly Roundup on the Cannabis Sector & Psychedelic Sector(Yahoo Finance)
2024-11-14 07:00
GH Research Reports Third Quarter 2024 Financial Results and Provides Business Updates(GlobeNewswire)
2024-11-13 18:00
GH Research Reports Third Quarter 2024 Financial Results and Provides Business Updates(Globenewswire)
2024-11-10 07:06
We Think GH Research (NASDAQ:GHRS) Can Afford To Drive Business Growth(Simply Wall St.)
2024-09-09 12:00
GH Research (GHRS) Moves to Buy: Rationale Behind the Upgrade(Zacks)
2024-09-09 09:35
After Plunging -18.19% in 4 Weeks, Here's Why the Trend Might Reverse for GH Research (GHRS)(Zacks)
2024-09-08 21:14
Weekly Roundup on the Cannabis Sector & Psychedelic Sector(Market Exclusive)
2024-09-03 10:24
GH Research Names Velichka Valcheva as CEO(MT Newswires)
2024-09-03 07:05
GH Research Reports Second Quarter 2024 Financial Results and Provides Business Updates(GlobeNewswire)
2024-09-03 07:00
GH Research Announces Appointment of Dr. Velichka “Villy” Valcheva to Chief Executive Officer(GlobeNewswire)
2024-09-02 19:05
GH Research Reports Second Quarter 2024 Financial Results and Provides Business Updates(Globenewswire)
2024-09-02 19:00
GH Research Announces Appointment of Dr. Velichka "Villy" Valcheva to Chief Executive Officer(Globenewswire)
2024-07-06 07:21
3 Psychedelic Stocks to Ride to the Moon and Beyond(InvestorPlace)
2024-07-05 19:21
3 Psychedelic Stocks to Ride to the Moon and Beyond(Investorplace)
2024-07-03 09:48
Psychedelic Picks: 3 Trippy Stocks Aiming for Out-of-This-World Returns(InvestorPlace)
2024-07-02 21:48
Psychedelic Picks: 3 Trippy Stocks Aiming for Out-of-This-World Returns(Investorplace)
2024-06-02 08:33
GH Research (NASDAQ:GHRS) Is In A Good Position To Deliver On Growth Plans(Simply Wall St.)
2024-05-13 08:50
Recent Price Trend in GH Research (GHRS) is Your Friend, Here's Why(Zacks)
2024-05-12 20:50
Recent Price Trend in GH Research (GHRS) is Your Friend, Here's Why(Zacks)
2024-05-10 09:55
Wall Street Analysts Predict a 166.89% Upside in GH Research (GHRS): Here's What You Should Know(Zacks)
2024-05-09 21:55
Wall Street Analysts Predict a 166.89% Upside in GH Research (GHRS): Here's What You Should Know(Zacks)
2024-05-03 07:00
GH Research Reports First Quarter 2024 Financial Results and Provides Business Updates(GlobeNewswire)
2024-05-03 01:53
GHRS Stock Earnings: GH Research Beats EPS for Q1 2024(Investorplace)
2024-05-02 19:00
GH Research Reports First Quarter 2024 Financial Results and Provides Business Updates(Globenewswire)
2024-03-05 09:55
How Much Upside is Left in GH Research PLC (GHRS)? Wall Street Analysts Think 321.28%(Zacks)
2024-03-04 20:55
How Much Upside is Left in GH Research PLC (GHRS)? Wall Street Analysts Think 321.28%(Zacks)
2024-02-29 07:00
GH Research Reports Full Year 2023 Financial Results and Provides Business Updates(GlobeNewswire)
2024-02-28 18:00
GH Research Reports Full Year 2023 Financial Results and Provides Business Updates(Globenewswire)
2024-01-18 16:30
GH Research Announces Grant of European Patent Covering all Mebufotenin (5-MeO-DMT) and Mebufotenin Salt Products For Use in the Treatment of Major Depressive Disorder and Treatment-Resistant Depression(GlobeNewswire)

Page 1 of 3

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.